Harvard Apparatus Regenerative Technology, Inc., a clinical stage biotechnology company, develops and commercializes regenerated organs for human transplant. The company is developing the HART-Trachea, which includes a scaffold, the patient's cells, and a bioreactor to restore the structure and/or function of a severely damaged trachea; and automated solid organ bioreactor that has the ability to seed cells on an organ scaffold and keep them sterile and healthy during the growth phase prior to transplant. Its pre-clinical stage products include human-sized synthetic scaffold prototypes for esophageal transplant. Harvard Apparatus Regenerative Technology, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
84 October Hill Road, Suite 11
Holliston, MA 01746
What Organs have been Regenerated?
The synthetic 3DTrachea will be the first commercial regenerated organ for transplant. HART is working with the leading regenerative medicine researchers and surgeons across the globe in their research involving a wide variety of organs. Materials that are used as an organ constructs are compatible with implantation into humans. Stem cells from the patient are introduced into the organ constructs and placed in a special bioreactor. The HARTbioreactors allow the growth of 3D organs with the same immunological characteristics as the host patient. Once this regenerative organ is in place, it is functionally and the medically correct for the specific host. Regenerated organs, unlike transplanted organs eliminate the need for expensive and harmful immuno suppressive drugs.
InBreath Bioreactor Used in World's Second Successful Synthetic Trachea Transplant
Harvard Bioscience's Bioreactor Grows a Synthetic Tissue-Engineered Trachea Used in World's First Successful Human Transplantation